Ana Alarcón Tomás

Fertility after CAR T-Cell Therapy, a Survey on Management and Outcomes from the Cellular Therapy and Immunobiology Working Party of the EBMT

Giorgio Orofino, Isabel Sánchez-Ortega, Juana Schwartz Mota, Cristina Castilla-Llorente et autres

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Giorgio Orofino, Victoria Grandage, Andrea Palasciano, Georg‐Nikolaus Franke et autres

it, nl, gb, de, il, es, ie, fr, cz (code pays fourni par la source)

Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy

Silvia Escribano-Serrat, Nishi Shah, Sigrun Einarsdottir, Ana Alarcón Tomás et autres

es, us (code pays fourni par la source)

Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma

Efrat Luttwak, David Nemirovsky, Sean M. Devlin, Giulio Cassanello et autres

us, it, es, ca, de (code pays fourni par la source)

A Pathway for Integrating Artificial Intelligence for Neonatal Neuromonitoring: From Code to Crib Side

Paweł Kułakowski, Ana Alarcón Tomás, Tamara Škorić, Silvia Seoni et autres

pl, es, rs, it, ie (code pays fourni par la source)

462 | OUTCOMES AFTER CAR‐T CELL THERAPY (TISAGENLECLEUCEL OR AXICABTAGENE CILOLEUCEL) IN PATIENTS OLDER THAN 70 YEARS WITH DIFFUSE LARGE B CELL LYMPHOMA

Vitória Manuele Passos da Silva Rocha, Jarl Mooyaart, Ron Ram, Katherine Clesham et autres

br, nl, il, gb, ch, fr, de, es, lb, it (code pays fourni par la source)

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

Alejandro Luna, Sean M. Devlin, Kai Rejeski, Jessica Flynn et autres

us, es, de, it (code pays fourni par la source)

Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee

Guillermo Ortí, Guillaume Dachy, Charlotte Graham, Zinaida Perić et autres

es, be, gb, hr, it, se, nl, sa, us, fr, au, de (code pays fourni par la source)

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

Sandeep Raj, Teng Fei, Shalev Fried, Andrew Ip et autres

us, il, es, ca (code pays fourni par la source)

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Charlotte Graham, Roser Velasco, Ana Alarcón Tomás, Orla Stewart et autres

gb, es, be, it, se, hr, nl, us, fr, de (code pays fourni par la source)

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

Victoria Gutgarts, Jessica Flynn, Sean M. Devlin, Adam Goldman et autres

us, il, es (code pays fourni par la source)

Supplementary Figure S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma

Harper Hubbeling, Doris Leithner, Emily A. Silverman, Jessica Flynn et autres